CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BGNASc.393T>CPrognosticSupportsPoor OutcomeIntrahepatic CholangiocarcinomaSchmitz et al., 2007
CPIK3CAC420RPredictiveDoes Not SupportResistanceColorectal CancerCetuximabDe Roock et al., 2010
DKRASG12VPredictiveSupportsSensitivity/ResponseColorectal CancerDactolisib,SelumetinibMigliardi et al., 2012
CNRASG12DPredictiveSupportsResistanceColorectal CancerCetuximab,IrinotecanDe Roock et al., 2010
BKRASG12/G13PredictiveSupportsResistanceColorectal CancerPanitumumabAmado et al., 2008
BPIK3CAMutationPrognosticSupportsBetter OutcomeBreast CancerKalinsky et al., 2009
DPIK3CAE545KPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerTrastuzumab EmtansineBaselga et al., 2016
BPIK3CAWildtypePredictiveDoes Not SupportSensitivity/ResponseColorectal CancerAspirinLiao et al., 2012
DPTENLossPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPictilisibO'Brien et al., 2010
DERBB2AmplificationPredictiveSupportsSensitivity/ResponseBreast CancerPictilisibO'Brien et al., 2010
DPIK3CAC420RPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPictilisibO'Brien et al., 2010
BPIK3CAMutationPredictiveSupportsResistanceBreast CancerTrastuzumabRazis et al., 2011
DPIK3CAH1047LPredictiveSupportsSensitivity/ResponseBreast CancerPictilisibO'Brien et al., 2010
BPIK3CAMutationPredictiveSupportsResistanceHer2-receptor Positive Breast CancerTrastuzumabRazis et al., 2011
DPIK3CAH1047RPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerTrastuzumab EmtansineBaselga et al., 2016
BPIK3CAMutationPrognosticSupportsPoor OutcomeColorectal CancerKato et al., 2007
BBRAFV600EPredictiveSupportsResistanceColorectal CancerPanitumumab,CetuximabDi Nicolantonio et al., 2008
BBRAFV600EPrognosticSupportsPoor OutcomeColorectal CancerSouglakos et al., 2009
BBRAFV600EPredictiveSupportsResistanceColorectal CancerOxaliplatinSouglakos et al., 2009
BBRAFV600EPredictiveSupportsResistanceColorectal CancerIrinotecanSouglakos et al., 2009
BBRAFV600EPredictiveSupportsResistanceColorectal CancerOxaliplatin,Bevacizumab,CapecitabineTol et al., 2009
BEGFRT790MPredictiveSupportsResistanceLung Non-small Cell CarcinomaGefitinibKosaka et al., 2006
DEGFRT790MPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDacomitinibEngelman et al., 2007
DBCR::ABL1Fusion AND ABL1 F359VPredictiveSupportsResistanceChronic Myeloid LeukemiaNilotinibRedaelli et al., 2009
CKRASG13DPredictiveSupportsResistanceColorectal CancerPanitumumabDe Roock et al., 2010
CNRASQ61LPredictiveSupportsResistanceColorectal CancerIrinotecan,CetuximabDe Roock et al., 2010
BBRAFMutationPredictiveSupportsResistanceColorectal CancerCetuximab,ChemotherapyDe Roock et al., 2010
CNRASQ61KPredictiveSupportsResistanceColorectal CancerCetuximab,ChemotherapyDe Roock et al., 2010
DNRASQ61KPredictiveSupportsSensitivity/ResponseColorectal CancerDactolisib,SelumetinibMigliardi et al., 2012
CKRASG12DPredictiveSupportsResistanceColorectal CancerPanitumumabDe Roock et al., 2010
CBRAFD594GPredictiveDoes Not SupportResistanceColorectal CancerCetuximab,IrinotecanDe Roock et al., 2010
DKRASA146TPredictiveSupportsSensitivity/ResponseColorectal CancerSelumetinib,DactolisibMigliardi et al., 2012
BKRASG12DPredictiveSupportsResistanceColorectal CancerCetuximabDe Roock et al., 2010
DKRASA146VPredictiveSupportsSensitivity/ResponseColorectal CancerDactolisib,SelumetinibMigliardi et al., 2012
CPIK3CAE545QPredictiveDoes Not SupportResistanceColorectal CancerCetuximab,IrinotecanDe Roock et al., 2010
CPIK3CAE545KPredictiveDoes Not SupportResistanceColorectal CancerCetuximabDe Roock et al., 2010
DKRASG12DPredictiveSupportsSensitivity/ResponseColorectal CancerSelumetinib,DactolisibMigliardi et al., 2012
BKRASG12VPredictiveSupportsResistanceColorectal CancerCetuximabDe Roock et al., 2010
DATMT2666APredictiveSupportsResistanceChronic Lymphocytic LeukemiaDoxorubicinNavrkalova et al., 2013
DATMR3008CPredictiveSupportsResistanceChronic Lymphocytic LeukemiaDoxorubicinNavrkalova et al., 2013
DATMc.902-1G>TPredictiveSupportsResistanceChronic Lymphocytic LeukemiaDoxorubicinNavrkalova et al., 2013
CKRASA146PPredictiveSupportsResistanceColorectal CancerIrinotecan,CetuximabLoupakis et al., 2009
BKRASG12/G13PrognosticDoes Not SupportPoor OutcomeColorectal CancerAmado et al., 2008
CKRASG12CPredictiveSupportsResistanceColorectal CancerPanitumumabAmado et al., 2008
CTP53R273CPredictiveDoes Not SupportSensitivity/ResponseStomach CarcinomaCisplatin,Mitomycin,EtoposideBataille et al., 2003
CTP53Y220CPredictiveSupportsSensitivity/ResponseStomach CarcinomaCisplatin,Mitomycin,EtoposideBataille et al., 2003
DIDH1R132CPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaBPTESEmadi et al., 2014
DPIK3CAC420RPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerTrastuzumab EmtansineBaselga et al., 2016
BPIK3CAMutationPredictiveSupportsResistanceLung Non-small Cell CarcinomaGefitinib,ErlotinibLudovini et al., 2011
BKRASExon 2 MutationPrognosticDoes Not SupportPoor OutcomeColorectal CancerKato et al., 2007
Page 40 of 96
PreviousNext